Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids [Yahoo! Finance]
Rhythm Pharmaceuticals, Inc. (RYTM)
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rhythmtx.com
Company Research
Source: Yahoo! Finance
its only marketed drug, Imcivree (setmelanotide), to treat obesity in children as young as two years old, under the Priority Review pathway. A filing designated as a Priority Review reduces the review period to four months. A final decision from the FDA is expected on Dec. 26, 2024. Imcivree, an MC4R agonist, is already approved in the United States and EU for chronic weight management in adult and pediatric patients aged six years and older. The eligible patient population includes those with monogenic or syndromic obesity due toBardet-Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. Rhythm's sNDA is looking to expand the eligible patient population for the drug by lowering the minimum required age to receive Imcivree treatment to two years in the United States. In July 2024, the drug's label was expanded in the EU to include children aged two years with obesity due to BBS o
Show less
Read more
Impact Snapshot
Event Time:
RYTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RYTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RYTM alerts
High impacting Rhythm Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RYTM
News
- Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength? [Yahoo! Finance]Yahoo! Finance
- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $64.00 price target on the stock.MarketBeat
- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $64.00 price target on the stock.MarketBeat
- Rhythm Pharmaceuticals Announces New Employment Inducement GrantsGlobeNewswire
- Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade) [Seeking Alpha]Seeking Alpha
RYTM
Earnings
- 8/6/24 - Beat
RYTM
Sec Filings
- 9/19/24 - Form 8-K
- 9/19/24 - Form 4
- 9/17/24 - Form 144
- RYTM's page on the SEC website